References
- Vongvaivanich K, Lertakyamanee P, Silberstein SD, et al. Late-life migraine accompaniments: a narrative review. Cephalalgia. 2015;35:894–911.
- Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13(Suppl 2):S31–S70.
- Ferrari A, Baraldi C, Licata M, et al. Polypharmacy among headache patients: a cross-sectional study. CNS Drugs. 2018 May 11;32:567–578.
- Gentile G, Cipolla F, Capi M, et al. Precise medical decision making in geriatric anti-depressant therapy. Expert Rev Precision Med Drug Dev. 2016;1:387–396.
- Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet. 2000;3:271–290.
- Boyce RD, Handler SM, Karp JF, et al. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother. 2012;10:139–150.
- Nagler EV, Webster AC, Vanholder R, et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27:3736–3745.
- Sommer B, Fenn H. Review of topiramate for the treatment of epilepsy in elderly patients. Clin IntervAging. 2010;5:89–99.
- Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, et al. Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667–1676.
- Lionetto L, Borro M, Curto M, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12(4):399–406.
- [cited 2018 Jul 30]. Available from: http://www.drugbank.ca/[last
- [cited 2018 Jul 30]. Available from: http://bioinformatics.charite.de/supercyp/
- Robbins MS, Lipton RB. Management of headache in the elderly. Drugs Aging. 2010;27:377–398.
- Capi M, de Andrés F, Lionetto L, et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017;26:227–234.
- Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging. 2006;23(6):461–489.
- Wongrakpanich S, Wongrakpanich A, Melhado K, et al. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9:143–150.
- Rochester MP, Kane AM, Linnebur DR. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. Ther Adv Drug Saf. 2018;9:297–308.